Patents by Inventor Masafumi Ihara
Masafumi Ihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11925633Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: GrantFiled: December 18, 2020Date of Patent: March 12, 2024Assignee: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Tadamasa Matsumoto, Masafumi Ihara, Satoshi Saito, Masanori Fukushima
-
Publication number: 20230416823Abstract: The present invention chiefly aims to provide a new method of detecting or determining ApoE genetic polymorphism, that is rapid and less invasive to the subject. The present invention includes, for example, a method for detecting a genetic polymorphism of apolipoprotein E present in genomic DNA collected from a subject, comprising the following steps 1 to 3: 1. a step of preparing a specimen with DNA released from saliva; 2. a step of adding the followings to the specimen containing the DNA and then mixing: (1) a PCR enzyme, (2) a PCR primer pair for amplifying a nucleic acid fragment of the apolipoprotein E gene, and (3) a fluorescent labeled probe set which has oligonucleotides for detecting the genetic polymorphism of apolipoprotein E; and 3. a step of performing PCR, and measuring the fluorescence intensities according to the genetic polymorphism of apolipoprotein E from the PCR product.Type: ApplicationFiled: October 6, 2021Publication date: December 28, 2023Applicants: Shimadzu Corporation, National Cerebral and Cardiovascular CenterInventors: Daisuke Kawakami, Masafumi Ihara
-
Publication number: 20230270737Abstract: The present disclosure provides a method of preventing or delaying the progression from mild cognitive impairment (MCI) to dementia or a therapeutic agent therefor.Type: ApplicationFiled: May 6, 2021Publication date: August 31, 2023Applicants: Shimadzu Corporation, National Cerebral and Cardiovascular CenterInventors: Daisuke Kawakami, Masafumi Ihara, Satoshi Saito
-
Publication number: 20220401043Abstract: A cerebral infarction treatment support system (100) includes a detection device (10), a display (30), and an image controller (20), and the image controller (20) includes a receiver (21) configured to receive at least one of first information (41) generated by the detection device (10) or second information (42) related to a susceptibility gene generated based on the first information (41), and a video output (22) configured to output at least one of the received first information (41) or second information (42) to the display (30).Type: ApplicationFiled: October 28, 2020Publication date: December 22, 2022Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATIONInventors: Masafumi IHARA, Takeshi YOSHIMOTO, Daisuke KAWAKAMI
-
Publication number: 20220265603Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.Type: ApplicationFiled: June 24, 2020Publication date: August 25, 2022Applicants: NATIONAL HOSPITAL ORGANIZATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Advanced Innovation Development Co., Ltd., FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Noriko ASAHARA, Takayuki INOUE, Masashi TANAKA, Masafumi IHARA, Satoshi SAITO
-
Publication number: 20210100790Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: ApplicationFiled: December 18, 2020Publication date: April 8, 2021Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Tadamasa MATSUMOTO, Masafumi IHARA, Satoshi SAITO, Masanori FUKUSHIMA
-
Publication number: 20200190590Abstract: Provided is a method for predicting probability of ischemic stroke onset. A method for predicting a risk of ischemic stroke onset, the method comprising: a detection step of detecting presence or absence of a RNF213 p.R4810K gene variant in a sample derived from a test subject who does not develop ischemic stroke; and a determination step of determining whether a probability of ischemic stroke onset of the test subject is high or not, based on the presence or absence of the RNF213 p.R4810K gene variant in the detection step, and gender information of the test subject. A genetic marker for predicting a risk of ischemic stroke onset using gender information, comprising a RNF213 p.R4810K gene variant. A biomarker for predicting a risk of ischemic stroke onset using gender information, comprising a polypeptide encoded by a RNF213 p.R4810K gene variant.Type: ApplicationFiled: December 10, 2019Publication date: June 18, 2020Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, SHIMADZU CORPORATIONInventors: Masafumi IHARA, Shuhei OKAZAKI, Daisuke KAWAKAMI
-
Publication number: 20190142820Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: ApplicationFiled: May 1, 2017Publication date: May 16, 2019Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Tadamasa MATSUMOTO, Masafumi IHARA, Satoshi SAITO, Masanori FUKUSHIMA
-
Patent number: 10080812Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.Type: GrantFiled: February 24, 2016Date of Patent: September 25, 2018Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.Inventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki
-
Patent number: 10081630Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.Type: GrantFiled: February 24, 2016Date of Patent: September 25, 2018Assignees: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.Inventors: Masahiro Ono, Hideo Saji, Masafumi Ihara, Hiroki Matsumoto, Ikuya Seki
-
Patent number: 10016409Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: GrantFiled: July 14, 2017Date of Patent: July 10, 2018Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
-
Publication number: 20180000974Abstract: The present invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a definite general formula or a salt thereof, or a radiopharmaceutical comprising the same.Type: ApplicationFiled: February 24, 2016Publication date: January 4, 2018Applicants: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.Inventors: Hideo SAJI, Masahiro ONO, Masafumi IHARA, Ikuya SEKI
-
Publication number: 20170362226Abstract: The present invention relates to a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, or a radiopharmaceutical comprising the same.Type: ApplicationFiled: February 24, 2016Publication date: December 21, 2017Applicants: KYOTO UNIVERSITY, NIHON MEDI-PHYSICS CO., LTD.Inventors: Masahiro ONO, Hideo SAJI, Masafumi IHARA, Hiroki MATSUMOTO, Ikuya SEKI
-
Publication number: 20170312265Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: July 14, 2017Publication date: November 2, 2017Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi IHARA, Takakuni MAKI, Akihiko TAGUCHI
-
Patent number: 9737524Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: GrantFiled: September 21, 2015Date of Patent: August 22, 2017Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
-
Publication number: 20160008348Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: September 21, 2015Publication date: January 14, 2016Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATIONInventors: Masafumi IHARA, Takakuni MAKI, Akihiko TAGUCHI
-
Publication number: 20150152084Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.Type: ApplicationFiled: June 14, 2013Publication date: June 4, 2015Inventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
-
Publication number: 20140088306Abstract: Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound.Type: ApplicationFiled: August 26, 2013Publication date: March 27, 2014Applicants: Nihon Medi-Physics Co., Ltd., KYOTO UNIVERSITYInventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki